Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04130633 · ClinicalTrials.gov registry record · Phase 1
Behavioral Pharmacology of THC and Alpha-pinene
A Phase 1 study of THC and Alpha-pinene, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT04130633: Completed Phase 1 study of THC and Alpha-pinene, sponsored by Johns Hopkins University.
NCT04130633 is a Phase 1 study of THC and Alpha-pinene that has completed, run by Johns Hopkins University. The registered enrollment target is 33 participants, below the 53-participant average among 9 other THC trials with a reported enrollment target (38% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04130633, a Phase 1 study of THC and Alpha-pinene, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized alpha-pinene and THC administered via inhalation.
Primary Outcome
Mean Peak change from baseline rating (0-100) of Drug Effect on the DEQ, a visual analog scale (VAS) self-report questionnaire, with 0 being no effect and 100 being maximum effect.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG THC
- DRUG Alpha-Pinene
Study Locations (1)
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2020-11-05 |
| Est. Completion | 2024-03-08 |
| Phase | Phase 1 |
What the finished NCT04130633 record still lists
NCT04130633 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 53-participant average among 9 other THC trials with a reported enrollment target (38% lower).
The record links to 2 conditions, with THC appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04130633 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT04130633 about?
NCT04130633 is a clinical study titled "Behavioral Pharmacology of THC and Alpha-pinene". This study will evaluate the pharmacokinetics and pharmacodynamics of vaporized alpha-pinene and THC administered via inhalation.
What is the current status of trial NCT04130633?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 33 participants. The study started on 2020-11-05. Estimated completion is 2024-03-08.
What conditions does trial NCT04130633 study?
This clinical trial studies the following conditions: THC, Alpha-pinene.
What interventions are being tested in trial NCT04130633?
The interventions under investigation include: Placebo (DRUG), THC (DRUG), Alpha-Pinene (DRUG).
Who is sponsoring clinical trial NCT04130633?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04130633 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for THC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04130633's enrollment target sits among peer trials
33 6th of 9 higher than 4 of 9 other THC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other THC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Behavioral Pharmacology of Orally Administered THC and D-limonene
RECRUITING · Phase 1
-
THC Memory & Reward Learning Pilot
ACTIVE NOT RECRUITING · Phase 1
-
Pilot fMRI Studies of Aging-Related Effects of THC
RECRUITING · Phase 2
-
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
RECRUITING · Phase 2
-
Cannabis THC Potency, Metabolism, and Cognitive Impairment in Young Adults
RECRUITING · NA
-
Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI